Astrocyte-specific IKK2 activation in mice is sufficient to induce neuroinflammation but does not increase susceptibility to MPTP

Neurobiology of Disease

Volumn 48, Issue 3, 2012, Pages 481-487

  Oeckl, Patrick ^a,c   Lattke, Michael ^b   Wirth, Thomas ^b   Baumann, Bernd ^b   Ferger, Boris ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Nuvisan GmbH   (Germany)

Author keywords

Astrocytes; IKK2; MPTP; Neuroinflammation; NF B; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTOKINE; DOPAMINE; I KAPPA B KINASE BETA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; ENZYME ACTIVATION; MALE; MICROGLIA; MOTOR ACTIVITY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

ANIMALS; ASTROCYTES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; I-KAPPA B KINASE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; MPTP POISONING; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84864947510     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.06.010     Document Type: Article

References (44)

1. Aleksic T., Baumann B., Wagner M., Adler G., Wirth T., Weber C.K. Cellular immune reaction in the pancreas is induced by constitutively active IkappaB kinase-2. Gut 2007, 56:227-236.
2. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J. Biol. Chem. 2004, 279:51647-51653.
3. 2+ accumulation. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9328-9332.
4. Baumann B., Wagner M., Aleksic T., von Wichert G., Weber C.K., Adler G., Wirth T. Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo. J. Clin. Invest. 2007, 117:1502-1513.
5. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
6. Brambilla R., Persaud T., Hu X., Karmally S., Shestopalov V.I., Dvoriantchikova G., Ivanov D., Nathanson L., Barnum S.R., Bethea J.R. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J. Immunol. 2009, 182:2628-2640.
7. Buck K., Ferger B. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiol. Dis. 2008, 29:210-220.
8. Byler S.L., Boehm G.W., Karp J.D., Kohman R.A., Tarr A.J., Schallert T., Barth T.M. Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice. Behav. Brain Res. 2009, 198:434-439.
9. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 2003, 60:1059-1064.
10. Chertoff M., Di P.N., Schoeneberg A., Depino A., Ferrari C., Wurst W., Pfizenmaier K., Eisel U., Pitossi F. Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor alpha in the nigrostriatal dopaminergic circuit of adult mice. Exp. Neurol. 2011, 227:237-251.
11. Ciesielska A., Joniec I., Przybylkowski A., Gromadzka G., Kurkowska-Jastrzebska I., Czlonkowska A., Czlonkowski A. Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiol. Exp. (Wars) 2003, 63:117-126.
12. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14669-14674.
13. Dutta G., Zhang P., Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol. 2008, 22:453-464.
14. Ferger B., Leng A., Mura A., Hengerer B., Feldon J. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 2004, 89:822-833.
15. Gao H.M., Liu B., Zhang W., Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 2003, 17:1957-1959.
16. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 1996, 103:987-1041.
17. Ghosh A., Roy A., Liu X., Kordower J.H., Mufson E.J., Hartley D.M., Ghosh S., Mosley R.L., Gendelman H.E., Pahan K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18754-18759.
18. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
19. Goralski K.B., Renton K.W. Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats. Toxicol. Appl. Pharmacol. 2004, 196:381-389.
20. Grealish S., Mattsson B., Draxler P., Bjorklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur. J. Neurosci. 2010, 31:2266-2278.
21. Gutierrez H., Davies A.M. Regulation of neural process growth, elaboration and structural plasticity by NF-kappaB. Trends Neurosci. 2011, 34:316-325.
22. Harari O.A., Liao J.K. NF-kappaB and innate immunity in ischemic stroke. Ann. N. Y. Acad. Sci. 2010, 1207:32-40.
23. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
24. Herrmann O., Baumann B., de Lorenzi R., Muhammad S., Zhang W., Kleesiek J., Malfertheiner M., Kohrmann M., Potrovita I., Maegele I., Beyer C., Burke J.R., Hasan M.T., Bujard H., Wirth T., Pasparakis M., Schwaninger M. IKK mediates ischemia-induced neuronal death. Nat. Med. 2005, 11:1322-1329.
25. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
26. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7531-7536.
27. Ito D., Imai Y., Ohsawa K., Nakajima K., Fukuuchi Y., Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 1998, 57:1-9.
28. Karin M. The IkappaB kinase - a bridge between inflammation and cancer. Cell Res. 2008, 18:334-342.
29. Kreitzer A.C., Malenka R.C. Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60:543-554.
30. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 1999, 156:50-61.
31. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
32. Pascual O., Casper K.B., Kubera C., Zhang J., Revilla-Sanchez R., Sul J.Y., Takano H., Moss S.J., McCarthy K., Haydon P.G. Astrocytic purinergic signaling coordinates synaptic networks. Science 2005, 310:113-116.
33. Patel A., Toia G.V., Colletta K., Bradaric B.D., Carvey P.M., Hendey B. An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity. Exp. Neurol. 2011, 231:160-170.
34. Qian L., Flood P.M., Hong J.S. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J. Neural Transm. 2010, 117:971-979.
35. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 2004, 279:1415-1421.
36. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
37. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 2001, 108:1263-1282.
38. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119:7-35.
39. Sriram K., Miller D.B., O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 2006, 96:706-718.
40. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518.
41. Teismann P., Schwaninger M., Weih F., Ferger B. Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. Neuroreport 2001, 12:1049-1053.
42. Wilson E.H., Weninger W., Hunter C.A. Trafficking of immune cells in the central nervous system. J. Clin. Invest. 2010, 120:1368-1379.
43. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
44. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002, 35:419-432.